AC-P19

General Information


DRACP ID  DRACP04526

Peptide Name   AC-P19

Sequence  FAKKLAKLKKKLAKLALAL

Sequence Length  19

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C102H186N26O20

Absent amino acids  CDEGHIMNPQRSTVWY

Common amino acids  K

Mass  241804

Pl  11.58

Basic residues  7

Acidic residues  0

Hydrophobic residues  12

Net charge  7

Boman Index  270

Hydrophobicity  38.42

Aliphatic Index  149.47

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  De Novo Design of AC-P19M, a Novel Anticancer Peptide with Apoptotic Effects on Lung Cancer Cells and Anti-Angiogenic Activity

Doi Not available

Year  2022

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  20464

DRACP is developed by Dr.Zheng's team.